» Articles » PMID: 15350383

Anastrozole, an Aromatase Inhibitor, and Medroxyprogesterone Acetate Therapy in Premenopausal Obese Women with Endometrial Cancer: a Report of Two Cases Successfully Treated Without Hysterectomy

Overview
Journal Gynecol Oncol
Date 2004 Sep 8
PMID 15350383
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hormonal therapy for endometrial cancer is occasionally warranted in the premenopausal woman who is interested in maintaining fertility. Combining progesterone with an agent that eliminates the adipose production of estrogen will theoretically be more effective than progesterone alone.

Cases: Two cases of reproductive-aged women with grade 1 endometrial cancer who were treated with medroxyprogesterone acetate and anastrozole daily for 3 and 6 months subsequently reverted to normal endometrium.

Conclusion: Progesterone combined with the elimination of adipose production of estrogen may be an effective therapy in well-differentiated endometrial cancer in the obese premenopausal woman.

Citing Articles

Conservative treatment in early stage endometrial cancer: a review.

Trojano G, Olivieri C, Tinelli R, Damiani G, Pellegrino A, Cicinelli E Acta Biomed. 2020; 90(4):405-410.

PMID: 31910163 PMC: 7233769. DOI: 10.23750/abm.v90i4.7800.


A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer.

Zhang Z, Huang H, Feng F, Wang J, Cheng N J Gynecol Oncol. 2019; 30(4):e61.

PMID: 31074242 PMC: 6543109. DOI: 10.3802/jgo.2019.30.e61.


Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.

Stringer E, Fleming G Eur Endocrinol. 2018; 9(1):18-21.

PMID: 30349605 PMC: 6193520. DOI: 10.17925/EE.2013.09.01.18.


Successful treatment of low-grade endometrial cancer in premenopausal women with an aromatase inhibitor after failure with oral or intrauterine progesterone.

Straubhar A, Soisson A, Dodson M, Simons E Gynecol Oncol Rep. 2017; 21:10-12.

PMID: 28560298 PMC: 5443923. DOI: 10.1016/j.gore.2017.05.003.


Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.

Park J, Nam J Oncologist. 2015; 20(3):270-8.

PMID: 25673106 PMC: 4350794. DOI: 10.1634/theoncologist.2013-0445.